respiratori
tract
infect
second
lead
caus
mortal
morbid
worldwid
commun
acquir
sentinel
center
current
stcp
focus
test
influenza
respiratori
syncyti
viru
rsv
use
either
rapid
antigen
detect
rtpcr
test
patient
respiratori
symptom
requir
hospit
admiss
consequ
current
survey
system
substanti
limit
knowledg
regard
epidemiolog
relev
carv
type
season
carv
infect
allogen
hematopoiet
stem
cell
transplant
allohct
recipi
mirror
incid
infect
commun
howev
carv
infect
immunocompromis
patient
particular
recipi
allohct
sever
gener
popul
show
long
viral
shed
higher
rate
progress
upper
urtd
lower
respiratori
tract
diseas
lrtd
higher
mortal
rate
irrespect
carv
type
patient
stcp
focus
influenza
rsv
seem
suboptim
sinc
strategi
led
signific
mortal
rate
carv
lrtd
rang
fact
emphas
action
requir
improv
outcom
scenario
implement
prospect
intervent
clinic
carv
surveil
program
proclincarvsurp
transplant
center
expand
viru
detect
syndrom
multiplex
pcr
panel
firstlin
test
could
valu
aim
program
ideal
includ
follow
element
informationeduc
carv
infectionstransmiss
facil
immedi
riskassess
diagnosi
monitor
avail
highli
sensit
syndrom
multiplex
pcr
platform
realtim
alert
system
practition
updat
carv
manag
protocol
includ
transmiss
control
measur
expect
clinic
benefit
would
identifi
carv
earlier
stage
diseas
begin
respiratori
symptom
hospit
admiss
limit
outbreak
situat
time
therapi
antivir
drug
support
care
measur
final
end
point
would
reduct
direct
carv
transmiss
progress
lrtd
hospit
andor
icu
admiss
mortal
indirect
carv
effect
air
flow
obstruct
bacteri
coinfect
copd
exacerb
andor
cardiovascular
event
allcaus
mortal
date
lack
studi
demonstr
clinic
benefit
conduct
program
compar
stcp
current
studi
analyz
effect
institut
proclincarvsurp
compar
clinic
outcom
allohct
recipi
document
carv
infect
implement
singl
transplant
center
spain
studi
includ
two
consecut
cohort
adult
year
allohct
recipi
microbiologicallydocu
carv
infect
diagnos
hematolog
divis
hospit
universitari
la
fe
valencia
spain
januari
decemb
institut
review
board
approv
studi
accord
declar
helsinki
inform
consent
obtain
patient
includ
prospect
cohort
first
cohort
retrospect
cohort
includ
allohct
recipi
document
carv
infect
episod
diagnos
januari
april
period
second
cohort
prospect
cohort
compris
consecut
allohct
recipi
molecularlydocu
carv
infect
diagnos
proclincarvsurp
may
decemb
period
januari
april
allohct
carv
stcp
focus
evalu
recipi
respiratori
symptom
gener
emerg
unit
influenza
ab
rsv
test
rapid
antigen
andor
nucleic
acid
amplif
detect
method
case
neg
result
respiratori
symptom
worsen
hospit
admiss
syndrom
multiplex
pcr
test
use
specimen
either
upper
lower
respiratori
tract
provid
radiolog
sign
suggest
viral
etiolog
ground
glass
opac
interstiti
infiltr
bilater
micronodul
influenza
treat
oseltamivir
rsv
lrtd
treat
aerol
ribavirin
may
carri
proclincarvsurp
transplant
unit
previous
describ
part
elsewher
main
chang
introduc
period
yearli
educationalinform
clinic
session
healthcar
worker
physician
nurs
recipi
pretranspl
workup
allohct
recipi
respiratori
symptom
underw
carv
screen
syndrom
multiplex
rtpcr
panel
firstlin
test
attend
recipi
respiratori
symptom
outpati
transplant
clinic
work
hour
transmiss
control
measur
reinforc
outpati
clinic
follow
guidelin
assess
immunodefici
score
index
isi
time
carv
screen
establish
electron
realtim
alert
system
posit
carv
result
treat
rsv
hpiv
oral
ribavirin
earli
stage
diseas
outpati
clinic
accord
prior
intervent
protocol
influenza
infect
treat
oseltamivir
dose
h
h
sever
case
case
long
last
symptom
week
rsv
hpiv
oral
ribavirin
given
load
dose
maximum
daili
dose
mgkg
outpati
clinic
wherea
aerol
ribavirin
h
cours
last
h
use
case
lrtd
also
boost
annual
flu
vaccin
awar
inform
final
prospect
collect
clinic
laboratori
variabl
time
carv
screen
detail
retrospect
proclincarvsurp
cohort
manag
provid
patient
method
supplementari
file
recipientscarv
episod
includ
current
studi
evid
diseas
relaps
carv
detect
recipi
die
develop
one
carv
episod
count
recent
carv
episod
mortal
previou
one
censor
aliv
time
follow
carv
episod
routin
check
carvneg
urtd
defin
combin
upper
respiratori
symptom
rhinorrhea
sinus
otiti
pharyng
well
posit
carv
diagnosi
pcr
test
upper
respiratori
sampl
absenc
lrtd
symptom
andor
indic
pulmonari
infiltr
chest
xray
ct
scan
radiolog
result
classifi
lrtd
possibl
probabl
confirm
previous
describ
probabl
episod
bronchoscopi
perform
patient
without
radiolog
proof
pulmonari
involv
patient
urtd
andor
lrtd
symptom
underw
nasopharyng
aspir
nasopharyng
swab
induc
sputum
test
bal
perform
patient
radiolog
sign
lrtd
whenev
possibl
januari
april
firstlin
carv
screen
base
influeza
rsv
rapid
antigen
detect
andor
nucleic
acid
amplif
test
naat
vitro
rapid
immunochromatograph
assay
detect
rsv
influenza
b
aler
binaxnow
r
andor
autom
simplexa
tm
flu
ab
vr
direct
assay
spx
focu
diagnost
cypress
ca
repectv
period
rtpcr
multiplex
platform
consist
pneumovir
dna
array
primari
object
evalu
clinic
benefit
proclincarvsurp
compar
threemonth
allcaus
mortal
time
carv
diagnosi
recipi
receiv
stcp
care
versu
diagnos
proclincarvsurp
care
secondari
endpoint
includ
identif
risk
factor
rf
associ
allcaus
mortal
overal
surviv
os
frequenc
compar
use
test
categor
variabl
differ
median
compar
use
mannwhitney
u
test
univari
multivari
analys
proclincarvsurp
clinic
biolog
variabl
associ
threemonth
allcaus
mortal
calcul
use
logist
regress
model
multivari
analysi
variabl
paramet
estim
show
p
valu
univari
analysi
final
includ
twosid
exact
p
valu
report
p
valu
consid
statist
signific
os
probabl
carv
episod
accord
differ
clinic
biolog
variabl
estim
time
carv
detect
use
kaplanmei
curv
univari
comparison
made
logrank
test
data
analyz
spss
version
statist
packag
overal
allohct
recipi
retrospect
cohort
prospect
cohort
develop
episod
carv
urtd
andor
lrtd
carv
episod
retrospect
cohort
prospect
cohort
clinic
transplant
characterist
cohort
detail
tabl
studi
popul
compris
highrisk
cohort
sinc
recipi
allograft
altern
donor
adult
unrel
donor
urd
singl
cord
blood
unit
cbu
haploident
famili
donor
donorrecipi
human
leukocyt
antigen
hla
mismatch
consid
high
resolut
type
hla
b
c
repres
cohort
notabl
differ
among
cohort
includ
cbu
allohct
atg
use
retrospect
cohort
urd
prior
hct
reduc
intens
condit
regimen
prospect
cohort
p
comparison
tabl
summar
common
carv
type
isol
correspond
rate
urtd
lrtd
group
although
length
period
similar
retrospect
cohort
includ
carv
episod
recipi
wherea
prospect
cohort
includ
carv
episod
recipi
expect
carv
epidemiolog
differ
group
rsv
follow
influenza
viru
domin
retrospect
group
wherea
evrh
follow
rsv
common
carv
prospect
cohort
recipi
lrtd
significantli
higher
retrospect
cohort
prospect
cohort
p
patient
clinic
biolog
characterist
time
carv
infect
group
summar
tabl
carv
episod
diagnos
earlier
stem
cell
infus
prospect
cohort
median
day
vs
day
p
use
immunosuppress
drug
higher
isi
score
significantli
overrepres
retrospect
cohort
p
comparison
carv
infect
group
character
higher
rate
fever
hospit
admiss
antivir
therapi
p
comparison
regard
time
antivir
therapi
ribavirin
oseltamivir
rsv
influenza
case
compar
median
time
start
antivir
therapi
stcp
vs
proclincarvsurp
cohort
although
proclincarvsurp
cohort
start
antivir
earli
median
day
rang
day
vs
day
rang
differ
reach
statist
signific
p
also
compar
time
antivir
therapi
stcp
cohort
recipi
rsv
andor
influenza
virus
diagnos
rapid
detect
technic
compar
diagnos
syndrom
multiplex
rtpcr
second
diagnost
step
among
episod
rsv
andor
influenza
rsv
influenza
vr
influenza
episod
diagnos
rapid
detect
test
wherea
episod
diagnos
syndrom
multiplex
pcr
second
step
eight
case
diagnos
pcr
receiv
antivir
compar
diagnos
rapid
test
p
median
time
day
start
antivir
therapi
time
diagnosi
day
rang
rapid
detect
cohort
vs
day
rang
multiplex
pcr
cohort
p
day
mortal
rapid
test
cohort
vs
multiplex
pcr
group
p
death
day
carv
diagnosi
occur
carv
episod
versu
carv
episod
retrospect
prospect
cohort
respect
p
median
time
death
day
rang
day
rang
stem
cell
infus
respect
overal
threemonth
allcaus
mortal
recipi
retrospect
cohort
versu
recipi
prospect
cohort
p
differ
mortal
even
higher
recipi
carv
lrtd
retrospect
cohort
vs
p
compar
caus
death
differ
time
point
among
cohort
find
signific
differ
retrospect
cohort
recipi
die
day
carv
document
due
mix
bacterialcarv
coinfect
n
carvrel
respiratori
failur
n
fungalcarv
coinfect
n
gvhd
n
diseas
relaps
n
day
addit
recipi
die
due
mix
bacterialcarv
coinfect
n
carv
n
fungalcarv
coinfect
n
bacteri
infect
n
gvhd
n
relaps
n
final
recipi
die
day
due
carvrel
respiratori
failur
n
fungalcarv
coinfect
n
gvhd
n
relaps
n
prospect
cohort
recipi
die
day
due
carvrel
respiratori
failur
n
pulmonari
secondari
malign
n
two
recipi
die
day
one
due
carv
respiratori
failur
anoth
caus
sever
gvhd
hemorrhag
six
addit
recipi
die
day
due
bacteri
infect
n
carvrel
respiratori
failur
n
diseas
relaps
n
logist
regress
univari
multivari
analys
rf
threemonth
allcaus
mortal
overal
carv
infect
episod
lrtd
shown
tabl
studi
evalu
recipientepisod
pair
identifi
transplant
carv
condit
associ
mortal
multivari
analysi
identifi
four
rf
donorrecipi
hla
mismatch
odd
ratio
confid
interv
ci
p
carv
lower
respiratori
tract
diseas
ci
p
highrisk
isi
score
ci
p
proclincarvsurp
ci
p
analyz
episod
carv
involv
lrtd
determin
rf
mortal
case
n
multivari
analysi
identifi
three
independ
rf
associ
mortal
donorrecipi
hla
mismatch
highrisk
isi
score
tabl
clinic
biolog
characterist
respiratori
viru
infect
episod
allohsct
recipi
accord
prospect
clinic
carv
survey
vs
retrospect
standard
clinic
practic
retrospect
carv
p
valu
n
n
immunodefici
score
index
n
anc
l
carv
infect
retrospect
cohort
lower
threemonth
os
carv
diagnosi
vs
p
likewis
os
significantli
lower
allohct
recipi
carv
lrtd
retrospect
cohort
vs
respect
p
fig
b
os
accord
variabl
previous
identifi
rf
mortal
also
significantli
lower
retrospect
cohort
tabl
studi
show
applic
proclincarvsurp
allohct
recipi
independ
associ
reduc
threemonth
allcaus
mortal
carv
compar
influenza
rsvbase
stcp
signific
decreas
mortal
rate
observ
rel
number
vs
carv
episod
retrospect
proclincarvsurp
cohort
respect
significantli
absolut
number
recipi
vs
recipi
retrospect
proclincarvsurp
cohort
respect
addit
found
donorrecipi
hla
mismatch
carv
lrtd
highrisk
isi
also
associ
higher
mortal
differ
mortal
report
herein
prompt
sever
question
mortal
rate
retrospect
cohort
abnorm
high
first
observ
unusu
high
proport
moder
highrisk
isi
suggest
stcp
mostli
focus
recipi
higher
risk
howev
mortal
rate
differ
carv
type
lrtd
cohort
evrh
rsv
influenza
hpiv
hmpv
insid
interv
previous
report
rang
allohct
recipi
evrh
lrtd
rsv
lrtd
influenza
lrtd
hpiv
lrtd
final
hmpv
lrtd
second
retrospect
cohort
subject
select
bia
retrospect
studi
report
sever
case
captur
document
carv
infect
retriev
data
microbiolog
electron
system
cross
data
transplant
databas
data
rather
point
inaccuraci
stcp
carv
screen
select
recipi
sever
featur
lrtd
stage
fever
requir
hospit
admiss
addit
observ
like
lower
sensit
rapid
detect
technic
might
delay
diagnosi
importantli
start
antivir
drug
day
vs
day
p
signific
proport
recipi
rsv
influenza
initi
test
neg
rapid
detect
technic
although
statist
signific
recipi
show
higher
mortal
rate
stcp
cohort
vs
p
find
support
idea
stcp
result
delay
start
antivir
therapi
signific
number
recipi
may
also
help
explain
part
differ
mortal
among
period
third
cohort
compar
given
high
proport
risk
condit
associ
mortal
lower
number
carv
episod
retrospect
cohort
fact
cohort
differ
risk
condit
direct
consequ
differ
carv
screen
manag
strategi
period
howev
outcom
comparison
match
accord
highrisk
condit
carv
mortal
also
observ
significantli
wors
outcom
retrospect
cohort
see
tabl
therefor
data
suggest
stcp
like
led
carv
screen
highrisk
recipi
sever
featur
delay
start
antivir
therapi
consequ
poorer
outcom
wherea
proclincarvsurp
led
screen
treat
carv
earlier
larger
number
recipi
consequ
improv
outcom
threemonth
allcaus
mortal
rate
observ
proclincarvsurp
cohort
compar
favor
previous
report
especi
recipi
lrtd
low
mortal
rate
found
current
studi
support
valu
proclincarvsurp
reduc
mortal
assumpt
support
prior
experi
anoth
institut
run
proclincarvsurp
allohct
recipi
achiev
low
mortal
rate
recipi
rsv
andor
hpiv
lrtd
although
suppos
sever
element
proclincarvsurp
significantli
contribut
encourag
result
opinion
improv
three
major
key
point
first
decis
use
syndrom
multiplex
rtpcr
panel
primari
carv
test
factor
undoubtedli
increas
sensit
specif
compar
rapid
detect
technic
increas
carv
type
detect
consequ
larg
number
carv
episod
vs
carv
episod
recipi
vs
recipi
identifi
proclincarvsurp
cohort
second
carv
realtim
electron
alert
system
extrem
use
contact
recipi
test
posit
order
start
antivir
therapi
earlier
stage
diseas
third
identif
carv
earlier
stage
allow
us
earli
intervent
antivir
drug
mani
case
vs
carv
episod
treat
particularli
carv
urtd
vs
carv
urtd
episod
treat
rsv
urtd
vs
treat
hpiv
vs
treat
influenza
vs
treat
addit
proclincarvsurp
may
promot
closer
followup
recipi
carv
turn
could
contribut
identifi
treat
indirect
carv
effect
hypothes
observ
improv
carv
effect
antivir
drug
could
relat
sever
factor
first
identif
virus
recipi
airflow
obstruct
may
contribut
limit
misinterpret
pulmonari
pattern
gvhdrelat
obliter
bronchiol
avoid
corticosteroid
exposur
sure
reduc
carv
lrtd
sever
andor
risk
allcaus
mortal
second
close
clinic
monitor
recipi
document
carv
infect
may
led
earli
introduct
antibiot
case
bacteri
coinfect
suspicion
reduc
rate
hospit
admiss
proclincarvsurp
cohort
vs
consequ
limit
sever
indirect
carv
effect
sum
clinic
circumst
may
contribut
overal
improv
observ
carv
final
one
reward
effect
annual
clinic
carv
session
increas
awar
carv
infect
care
taken
healthcar
worker
includ
microbiologist
fellow
transplant
physician
nurs
altogeth
proclincarvsurp
may
contribut
toward
refin
carv
screen
collect
techniqu
process
greater
acuiti
identifi
recipi
mild
respiratori
symptom
timeli
feedback
posit
result
awar
carv
transmiss
rout
note
current
polici
also
translat
increas
influenza
vaccin
rate
also
sure
play
role
reduc
influenza
preval
influenza
lrtd
progress
hospit
admiss
note
studi
confirm
valu
isi
score
predict
mortal
sever
carv
type
isi
develop
investig
md
anderson
cancer
center
predict
lrtd
progress
mortal
allohct
rsv
highrisk
isi
categori
consist
predict
sever
respiratori
viru
infect
irrespect
carv
type
seri
although
implement
proclincarvsurp
time
resourc
consum
enthusiast
potenti
valu
reduc
allcaus
mortal
carv
infect
rel
short
time
like
applic
could
expand
medic
area
probabl
similar
benefit
nation
transnat
health
author
promot
program
tertiari
health
care
center
worldwid
give
prioriti
fund
world
health
organ
brave
initi
respiratori
viru
addit
program
could
bring
epidemiolog
data
realist
public
health
author
acknowledg
certain
limit
studi
inclus
sever
carv
type
use
two
differ
pcr
method
differ
minim
analyt
perform
nonprospect
random
studi
design
nonetheless
studi
strength
merit
consider
notabl
inclus
contemporari
cohort
molecular
era
prospect
data
collect
recent
cohort
conclus
provid
evid
establish
proclincarvsurp
base
multiplex
pcr
test
associ
major
clinic
benefit
reduc
threemonth
allcaus
mortal
allohct
recipi
carv
infect
prospect
studi
warrant
confirm
find
